Business Context and Reporting Period
Company: Protagonist Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 11, 2017
Event: Entry into an underwriting agreement for a public offering of common stock.
Key Financial Metrics
This filing details a capital raise rather than operational financial results. Key metrics related to the transaction include:
- Shares Offered: 3,530,000 shares of common stock.
- Public Offering Price: $17.00 per share.
- Price to Company: $15.98 per share (net of underwriting discounts).
- Expected Gross Proceeds: Approximately $60.0 million.
- Over-Allotment Option: Underwriters have a 30-day option to purchase up to 529,500 additional shares.
- Maximum Potential Proceeds: Approximately $69.0 million if the option is fully exercised.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the execution of the underwriting agreement with Leerink Partners LLC and Barclays Capital Inc. as representatives. The offering is expected to close on October 16, 2017, subject to customary closing conditions. Additionally, the company is updating its risk factor disclosures previously filed in its Form 10-Q for the quarter ended June 30, 2017.
Guidance, Outlook, and Risks
Management Commentary: The company is utilizing an effective registration statement on Form S-3 (No. 333-220314) to facilitate this offering. The underwriting agreement includes customary representations, warranties, indemnification obligations, and termination provisions.
Risks and Contingencies: The filing incorporates updated risk factor disclosures by reference to Exhibit 99.1. The closing of the transaction is contingent upon customary closing conditions.
Investor Verification Checklist
- Verify the final closing date of the offering (expected October 16, 2017).
- Confirm whether the underwriters exercise the option to purchase the additional 529,500 shares.
- Review the updated risk factors filed as Exhibit 99.1 for new material risks.
- Examine the Underwriting Agreement (Exhibit 1.1) for specific termination provisions and indemnification details.
- Check subsequent filings for the actual net proceeds received after deducting offering expenses.